EASTERN COOPERATIVE ONCOLOGY GROUP

描述(由申请人提供)：本申请旨在延续宾夕法尼亚大学37年来作为东部合作肿瘤学小组主要研究机构的角色。总体目标是继续作为该小组的科学和行政资源，将患者纳入ECOG方案，并协调和支持一个大型附属网络。在后一种作用中，这一应用程序将支持临床试验知识的传播，协助临床试验的适当进行，并使尽可能广泛的癌症患者能够接触到这些试验。尽管宾夕法尼亚大学在合作小组活动的所有方面都有出色的记录，包括应计、行政和科学投入以及数据质量，但该提案未来六年的具体目标是：1.继续提高所有疾病部位和方式的应计费用，超过我们目前的参与，特别是乳腺癌和肺癌。2.增加医生、护士和数据管理人员对小组活动的参与，包括制定礼仪。3.通过艾布拉姆森癌症中心网络吸引新的亲信，从而增加临床试验的可获得性。参与更大的社区这一项目与癌症最终治愈的相关性不言而喻。合作团体是制药行业以外的主力军，致力于明确测试新的治疗方法，不仅研究新药开发，还研究非药物治疗，如放射治疗和手术，将有Nooter资金。这些合作的小组活动，以及宾夕法尼亚大学的具体参与，代表了可以执行多模式、协作患者护理的最终模式的主要方式。ECOG的主要赠款详细描述了临床试验导致 相关性：恶性肿瘤仍然是美国个人和整个社会的巨大负担。如果没有公众对临床试验的支持，无论是通过财政支持还是参与临床试验，都不会取得进展。如果让私人掌握在手中，大片癌症治疗将得不到探索，使患者失去进步的可能性。

DESCRIPTION (provided by applicant): This application is being submitted to continue the University of Pennsylvania's role as a main institution in the Eastern Cooperative Oncology Group beyond its 37 years of continuous particpation. The overarching objectives are to continue to serve as a scientific and administrative resource for the Group, to enter patients onto ECOG protocols, and to coordinate and support a large affiliate network. In the latter role, this application will support the diffusion of knowledge of clinical trials, assist in the proper conduct of clinical trials, and make these trials accessible to the broadest possible population of patients with cancer. Although the University of Pennsylvania has had an outstanding track record in all aspects of cooperative group activities, including accrual, administrative and scientific input and data quality, the specific aims of the proposal for the next six years are to: 1. continue to enhance accrual in all disease site and modalities, beyong our current particpation, particularly in breast and lung cancers. 2. increase physician, nurse, and data management participation in Group activities, including protocol development. 3. attract new affilaites through the Abramson Cancer Center network, allowing for enhanced availability for clinical trials participation in the larger community The relevance of this project to the ultimate cure of cancer is self-evident. Cooperative groups are the main force outside of the pharmaceutical industry dedicated to the definitve tesing of new treatments, studying not just new drug development but also non-drug treatment, such as radiation therapy and surgery, for which there would be nooter funding. These cooperative group activities, and the specific involvement of the University of Pennsylvania, represent the chief way in which the ultimate model of multimodal, collaborative patient care can be performed. The main ECOG grant describes in detail the very specific way in which clinical trials have led to RELEVANCE: Malignancies remain an enormous burden for individuals in the United States and for society as a whole. Without public support of clinical trials, both by financial support as well as participation in clinical trials, progress will not be made. If left in private hands, large areas of cancer treatment will go unexplored, denying patients the possibility of progress.